Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14015678 | 0.86 | ADRB3 (0.39) | ADRB3ADRA2BADRA2C | |
| SCHEMBL14001907 | 0.85 | ADRB3 (0.49) | ADRB3ADRA2BADRA2CCYP3A4TSHR | |
| SCHEMBL12618519 | 0.85 | ADRB3 (0.40) | ADRB3ADRA2BADRA2C | |
| SCHEMBL12618503 | 0.83 | ADRB3 (0.38) | ADRB3ADRA2BADRA2C | |
| SCHEMBL12618491 | 0.83 | ADRB3 (0.38) | ADRB3ADRA2BADRA2CCYP2C19 | |
| SCHEMBL12618509 | 0.83 | ADRB3 (0.38) | ADRB3ADRA2BADRA2CCYP2C19 | |
| SCHEMBL15318736 | 0.81 | ADRB3 (0.46) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL8145663 | 0.81 | ADRB3 (0.46) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL13509140 | 0.80 | ADRB3 (0.47) | ADRB3ADRA2BADRA2CCYP3A4TSHR | |
| SCHEMBL12618532 | 0.79 | ADRB3 (0.52) | ADRB3ADRA2BADRA2CCYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951773-B2 | For treatment of hepatitis C | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-31 | — | — | US | disclosed |
| US-20080242835-A1 | Ring-Closing Metathesis Process for the Preparation of Macrocyclic Peptides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242835-A1 | Ring-Closing Metathesis Process for the Preparation of Macrocyclic Peptides | VIP, NGLY1, HPN | ADRB3 4386/4885ADRA2B 4715/4885ADRA2C 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.